Cherry Tree Wealth Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$57.7K Buy
2,056
+20
+1% +$532 0.01% 254
2025
Q4
$50.7K Sell
2,036
-3,589
-64% -$90.5K 0.01% 265
2025
Q3
$143K Buy
5,625
+21
+0.4% +$518 0.03% 189
2025
Q2
$136K Sell
5,604
-3,488
-38% -$81.3K 0.03% 189
2025
Q1
$230K Buy
9,092
+18
+0.2% +$471 0.06% 148
2024
Q4
$241K Buy
9,074
+19
+0.2% +$515 0.06% 149
2024
Q3
$262K Buy
9,055
+17
+0.2% +$496 0.06% 147
2024
Q2
$253K Buy
9,038
+17
+0.2% +$468 0.06% 146
2024
Q1
$250K Buy
9,021
+18
+0.2% +$499 0.06% 146
2023
Q4
$259K Buy
9,003
+15
+0.2% +$453 0.07% 135
2023
Q3
$298K Buy
8,988
+13
+0.1% +$460 0.09% 114
2023
Q2
$329K Buy
+8,975
New +$349K 0.1% 110

Other funds holding PFE

Cherry Tree Wealth Management's PFE Position: Q1 2026 in Review

Cherry Tree Wealth Management increased its Pfizer (PFE) stake by 0.98% in Q1 2026, buying an estimated $532 and bringing the position to 2,056 shares worth $57.7K. The position accounts for 0.01% of the portfolio, ranked #254.

Cherry Tree Wealth Management first reported a position in PFE in Q2 2023 and has held it in 12 quarters since. The position peaked at $329K in Q2 2023. 2,954 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Cherry Tree Wealth Management held 2,056 shares of Pfizer worth $57.7K as of Q1 2026.
  • Cherry Tree Wealth Management bought 20 Pfizer shares in Q1 2026, an estimated $532.
  • Pfizer made up 0.01% of Cherry Tree Wealth Management's portfolio in Q1 2026, its #254 holding.
  • Cherry Tree Wealth Management first reported a position in Pfizer in Q2 2023 and has held it in 12 quarters since.
  • Cherry Tree Wealth Management's Pfizer position peaked at $329K in Q2 2023.
  • 2,954 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Cherry Tree Wealth Management's 13F filing for Q1 2026, filed 5 May 2026.